Recent News

• 06.17.2025 - H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
• 06.09.2025 - Elemer Piros, PhD
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.02.2025 - atai and Beckley to Combine
• 06.02.2025 - atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
• 05.29.2025 - atai Life Sciences to Participate in Upcoming Investor Conferences
• 05.20.2025 - atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
• 05.14.2025 - atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Recent Filings

• 06.04.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 144 Report of proposed sale of securities
• 06.03.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.02.2025 - EX-99.1 EX-99.1
• 06.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.02.2025 - 8-K Current report
• 05.27.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors